Ideaya Biosciences Inc (NASDAQ:IDYA) shares, rose in value on Friday, March 07, with the stock price down by -3.20% to the previous day’s close as strong demand from buyers drove the stock to $18.46.
Actively observing the price movement in the last trading, the stock closed the session at $19.07. Referring to stock’s 52-week performance, its high was $47.44, and the low was $18.20. On the whole, IDYA has fluctuated by -26.45% over the past month.
With the market capitalization of Ideaya Biosciences Inc currently standing at about $1.62 billion, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 1.91M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that IDYA’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of IDYA currently trading nearly -10.77% and -19.10% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 31.20, while the 7-day volatility ratio is showing 6.32% which for the 30-day chart, stands at 5.29%. Furthermore, Ideaya Biosciences Inc (IDYA)’s beta value is 0.43, and its average true range (ATR) is 1.10.
A comparison of Ideaya Biosciences Inc (IDYA) with its peers suggests the former has fared considerably weaker in the market. IDYA showed an intraday change of -3.20% in last session, and over the past year, it shrunk by -58.82%%.
Data on historical trading for Ideaya Biosciences Inc (NASDAQ:IDYA) indicates that the trading volumes over the past 3 months, they’ve averaged 889.18K. According to company’s latest data on outstanding shares, there are 86.50 million shares outstanding.
Nearly 7.75% of Ideaya Biosciences Inc’s shares belong to company insiders and institutional investors own 100.99% of the company’s shares. The stock has fallen by -28.17% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the IDYA stock heading into the next quarter.
